Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) Research & Development (2023 - 2026)

Kura Oncology has reported Research & Development over the past 4 years, most recently at $65.3 million for Q1 2026.

  • Quarterly Research & Development rose 16.6% to $65.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $215.2 million through Mar 2026, up 13.46% year-over-year, with the annual reading at $251.1 million for FY2025, 47.72% up from the prior year.
  • Research & Development was $65.3 million for Q1 2026 at Kura Oncology, up from $56.0 million in the prior quarter.
  • Over five years, Research & Development peaked at $65.3 million in Q1 2026 and troughed at $25.2 million in Q1 2023.
  • The 4-year median for Research & Development is $38.0 million (2024), against an average of $40.6 million.
  • Year-over-year, Research & Development skyrocketed 60.66% in 2024 and then grew 16.6% in 2026.
  • A 4-year view of Research & Development shows it stood at $32.5 million in 2023, then skyrocketed by 60.66% to $52.3 million in 2024, then increased by 7.09% to $56.0 million in 2025, then grew by 16.6% to $65.3 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Research & Development are $65.3 million (Q1 2026), $56.0 million (Q1 2025), and $52.3 million (Q4 2024).